Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma.
Academic Medical Center, Department of Hematology, Amsterdam, The Netherlands. A.Hagenbeek@umcutrecht.nl
A
A
Hagenbeek
D006801:Humans; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy; D016499:Radioimmunotherapy; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D000069283:Rituximab; D015021:Yttrium Radioisotopes / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; C422802:ibritumomab tiuxetan; D019275:Radiopharmaceuticals; D000069283:Rituximab; D015021:Yttrium Radioisotopes